Format

Send to

Choose Destination
J Cutan Med Surg. 2012 Jul-Aug;16(4):257-60.

Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients.

Author information

1
Innovaderm Resarch Inc, Monreal, QC.

Abstract

BACKGROUND:

Current therapeutic options for extensive alopecia areata (AA) often lead to disappointing results.

OBJECTIVE:

To study the efficacy and safety of adalimumab in patients with severe AA.

METHODS:

This was a prospective, open-label, single-center, pilot study. Three subjects of the planned 10 were enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 mg followed by 40 mg SC every week for 6 months. Patients were evaluated for efficacy and safety on a monthly basis.

RESULTS:

Enrolment in this trial was stopped following publication of studies showing no improvement in patients with AA treated with tumor necrosis factor α antagonists. One patient had a favorable response to adalimumab, whereas the two other patients had no benefit from the therapy. Adalimumab was well tolerated by patients with AA.

CONCLUSION:

Adalimumab was well tolerated in patients with AA but did not induce clinically significant hair regrowth.

PMID:
22784518
DOI:
10.1177/120347541201600407
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center